Navigation Links
Harwood Feffer LLP Announces Investigation of Verenium Corporation

NEW YORK, Sept. 20, 2013 /PRNewswire/ -- Harwood Feffer LLP ( is investigating potential claims against the board of directors of Verenium Corporation ("Verenium" or the "Company") (NASDAQ: VRNM) concerning the proposed acquisition of the Company by BASF Corporation ("BASF").    

On September 20, 2013, Verenium announced that it had entered into a definitive agreement pursuant to which the Company will be acquired by BASF.  Under the terms of the agreement, Verenium shareholders will receive $4.00 per share.   

Our investigation concerns whether the Verenium board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company shareholders. 

If you own Verenium shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Benjamin I. Sachs-Michaels, Esq.
Robert I. Harwood, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website ( for more information about the firm.

Attorney Advertising © 2013 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter.

SOURCE Harwood Feffer LLP
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Applied Integrin Sciences, Inc. Announces Exceptional Results In Ovarian Cancer Study
2. BioConvergence®, Contract Manufacturing Organization for the Life Sciences Industry, Announces New Board of Directors
3. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
4. Natural Skin Care Solution, Probiotic Action Announces the Use of Their Probiotic Cleanser As a Anti-Acne Body Wash
5. Creabilis Announces Treatment of First Patients in its Phase 2b Trial of CT327 in Pruritus in Atopic Dermatitis Patients
6. Neogen announces 1st quarter results conference call
7. Global Industry Analysts, Inc. Announces the Launch of a Major Research Program Analysing the Global Market for Circulating Tumor Cells and Cancer Stem Cells
8. The tranSMART Foundation Announces New Version of the tranSMART Open Source Data Sharing Platform for the Life Sciences Community
9. Emmaus Life Sciences Announces Closing Of $7.5 Million Private Placement
10. AEgis Technologies Announces Official Launch of ADME WorkBench Software for Pharmacokinetics Prediction
11. Probiotics for Eczema Leader Announces New Developments in Using Probiotics for Children’s Eczema Relief
Post Your Comments:
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary Apte, ... their initial angel funding process. Now, they are paying it forward to other ... stage investments in the microbiome space. In this, they join other successful ...
(Date:11/24/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 2 at 9:30 a.m. ... and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola ... a corporate overview. --> th Annual Oppenheimer Healthcare ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... on behalf of the Toronto Stock Exchange, confirms that ... are no corporate developments that would cause the recent ... --> --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical ...
Breaking Biology Technology:
(Date:11/18/2015)... , November 18, 2015 ... has published a new market report titled  Gesture Recognition ... and Forecast, 2015 - 2021. According to the report, the global ... and is anticipated to reach US$29.1 bn by 2021, ... North America dominated the ...
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
(Date:11/10/2015)... 2015  In this report, the biomarkers ... product, type, application, disease indication, and geography. ... are consumables, services, software. The type segments ... efficacy biomarkers, and validation biomarkers. The applications ... development, drug discovery and development, personalized medicine, ...
Breaking Biology News(10 mins):